English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/181391
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorGallego-Durán, Rocíoes_ES
dc.contributor.authorCerro-Salido, Pabloes_ES
dc.contributor.authorGómez-González, Emilioes_ES
dc.contributor.authorPareja, María Jesúses_ES
dc.contributor.authorAmpuero, Javieres_ES
dc.contributor.authorRico, María Carmenes_ES
dc.contributor.authorAznar, Rafaeles_ES
dc.contributor.authorVilar-Gómez, Eduardoes_ES
dc.contributor.authorBugianesi, Elisabettaes_ES
dc.contributor.authorCrespo García, Javieres_ES
dc.contributor.authorGonzález-Sánchez, Francisco Josées_ES
dc.contributor.authorAparcero, Reyeses_ES
dc.contributor.authorMoreno-Santos, Inmaculadaes_ES
dc.contributor.authorSoto, Susanaes_ES
dc.contributor.authorArias-Loste, María Teresaes_ES
dc.contributor.authorAbad, Javieres_ES
dc.contributor.authorRanchal, Isidoraes_ES
dc.contributor.authorAndrade, Raúl J.es_ES
dc.contributor.authorCalleja, José Luises_ES
dc.contributor.authorPastrana, Migueles_ES
dc.contributor.authorLo lacono, Orestees_ES
dc.contributor.authorRomero-Gómez, Manueles_ES
dc.identifier.citationScientific Reports 6: 31421 (2016)es_ES
dc.description.abstractThere is a need, in NAFLD management, to develop non-invasive methods to detect steatohepatitis (NASH) and to predict advanced fibrosis stages. We evaluated a tool based on optical analysis of liver magnetic resonance images (MRI) as biomarkers for NASH and fibrosis detection by investigating patients with biopsy-proven NAFLD who underwent magnetic resonance (MR) protocols using 1.5T General Electric (GE) or Philips devices. Two imaging biomarkers (NASHMRI and FibroMRI) were developed, standardised and validated using area under the receiver operating characteristic curve (AUROC) analysis. The results indicated NASHMRI diagnostic accuracy for steatohepatitis detection was 0.83 (95% CI: 0.73–0.93) and FibroMRI diagnostic accuracy for significant fibrosis determination was 0.85 (95% CI: 0.77–0.94). These findings were independent of the MR system used. We conclude that optical analysis of MRI has high potential to define non-invasive imaging biomarkers for the detection of steatohepatitis (NASHMRI) and the prediction of significant fibrosis (FibroMRI) in NAFLD patients.es_ES
dc.description.sponsorshipThe research leading to these results has received funding from the European Community’s Seventh Framework Programme (FP7/2007–2013) under grant agreement #HEALTH-F2-2009-241762 for the project Fatty Liver Inhibition of Progression (FLIP) and from Consejería de Salud de la Junta de Andalucía under grant agreement #PI-0488-2012/2012. Imaging biomarkers (NASHMRI and FibroMRI) are protected by a European patent #EP15382118.es_ES
dc.publisherSpringer Naturees_ES
dc.relation.isversionofPublisher's versiones_ES
dc.titleImaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver diseasees_ES
dc.description.peerreviewedPeer reviewedes_ES
dc.contributor.funderEuropean Commissiones_ES
dc.contributor.funderJunta de Andalucíaes_ES
oprm.item.hasRevisionno ko 0 false*
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
srep31421.pdf498,42 kBAdobe PDFThumbnail
Show simple item record

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.